365 Eventually the use of gemtuzumab ozogamicin, a humanized anti-CD33 antibody, was found to bind to primary AML cells and was promising as an element for ADC-based therapies (Fig. 6). This evidence concerns the gene CD33 and acute myeloid leukemia.